Bayer completes acquisition of Visible Genetics:
This article was originally published in Clinica
Bayer Diagnostics (Tarrytown, New Jersey) has completed its $61.4m acquisition of Visible Genetics of Toronto, Canada (see Clinica No 1017, p 19). The purchase will enable Bayer to market Visible Genetics' Trugene HIV-1 genotyping test for HIV drug resistance alongside its own Versant family of HIV nucleic acid diagnostics tools, including the recently approved HIV-11 RNA 3.0 assay for viral load testing. Bayer expects the worldwide market for infectious disease testing to grow by 20% per year, reaching $1bn by 2005.